- Home
- AXL vs CRMD Comparison
AXL vs CRMD Comparison
Compare AXL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- CRMD
- Stock Information
- Founded
- AXL 1994
- CRMD 2006
- Country
- AXL United States
- CRMD United States
- Employees
- AXL N/A
- CRMD N/A
- Industry
- AXL Auto Parts:O.E.M.
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- CRMD Health Care
- Exchange
- AXL Nasdaq
- CRMD Nasdaq
- Market Cap
- AXL 739.6M
- CRMD 626.8M
- IPO Year
- AXL 1999
- CRMD 2010
- Fundamental
- Price
- AXL $6.31
- CRMD $10.33
- Analyst Decision
- AXL Hold
- CRMD Strong Buy
- Analyst Count
- AXL 4
- CRMD 5
- Target Price
- AXL $7.38
- CRMD $15.20
- AVG Volume (30 Days)
- AXL 2.0M
- CRMD 1.7M
- Earning Date
- AXL 11-08-2024
- CRMD 10-30-2024
- Dividend Yield
- AXL N/A
- CRMD N/A
- EPS Growth
- AXL N/A
- CRMD N/A
- EPS
- AXL 0.23
- CRMD N/A
- Revenue
- AXL $6,207,100,000.00
- CRMD $12,262,234.00
- Revenue This Year
- AXL $2.74
- CRMD N/A
- Revenue Next Year
- AXL N/A
- CRMD $277.75
- P/E Ratio
- AXL $27.23
- CRMD N/A
- Revenue Growth
- AXL 3.29
- CRMD 41184.20
- 52 Week Low
- AXL $5.43
- CRMD $2.89
- 52 Week High
- AXL $8.99
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- AXL 52.56
- CRMD 47.62
- Support Level
- AXL $5.71
- CRMD $11.27
- Resistance Level
- AXL $6.79
- CRMD $12.40
- Average True Range (ATR)
- AXL 0.25
- CRMD 0.89
- MACD
- AXL 0.04
- CRMD -0.17
- Stochastic Oscillator
- AXL 57.89
- CRMD 20.90
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.